Odyssey Therapeutics Posts Q2 Loss, Cash Runway Into 2028; Key Trials on Track
ODTX sits 20% above its 52-week low of $15.1.
Summary
Odyssey reported Q2 2026 financials with a net loss of $52.8M, up from $41.2M a year ago, driven by higher R&D spending as it advances its pipeline. Cash stands at $433.1M, expected to fund operations into the second half of 2028. The company confirmed that positive Phase 2a data for its lead candidate OD-001 will be presented at UEG Week in October, and it plans to initiate both a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab in the second half of 2026. A CTA filing for its second program, OD-002, is also expected by year-end. This follows the June proof-of-concept data that sent shares higher; the update provides concrete timelines and financial footing, though no new efficacy data is included. The cash runway extension reduces near-term dilution risk, but the increased loss reflects the cost of advancing multiple trials.
At the time of this announcement, ODTX was trading at $18.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $870.8M. The 52-week trading range was $15.10 to $20.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.